# A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

> **NCT01894568** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 388 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Peglispro
- **DRUG:** Insulin Glargine
- **DRUG:** Oral Antihyperglycemic Medications (OAMs)

## Key facts

- **NCT ID:** NCT01894568
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01894568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01894568, "A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01894568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*